Ilmix Group

Ilmix Group is a Russian biotechnology company based in the Skolkovo Innovation Center that specializes in the development of advanced drug delivery systems. The company utilizes a proprietary micellar technology platform to enhance the solubility and bioavailability of pharmaceutical compounds, particularly for respiratory and oncological applications. Its lead product, Ilmix, is a micellar formulation of favipiravir developed as an inhaled or nasal treatment for COVID-19. Ilmix Group aims to improve the therapeutic profile of established drugs by reformulating them into more effective delivery formats. The company's research and development efforts are focused on creating high-performance medications with reduced side effects and improved patient compliance.